健康元：公司在抗流感领域的核心产品推进成效显著

Core Viewpoint - The company is making significant progress in the field of anti-influenza products, with its core product, the innovative drug Marpaviroc capsules, nearing the final stages of review and set to be launched soon [1] Product Development - The Marpaviroc dry suspension for children has successfully entered Phase III clinical trials, indicating strong advancement in pediatric formulations [1] - The drug has notable advantages, including the ability to precisely block the replication of both influenza A and B viruses from the source, requiring only a single oral dose to complete the entire treatment course [1] - The pediatric formulation is highly adaptable and presents a low risk of resistance, with good safety profiles [1] Market Strategy - The company aims to accelerate the subsequent rollout of both products, striving to provide high-quality and convenient influenza treatment solutions for all age groups [1]